Methylene Blue: Magic Bullet for Vasoplegia?

Anesthesia and Analgesia

Volumn 122, Issue 1, 2016, Pages 194-201

  Hosseinian, Leila ^a   Weiner, Menachem ^a   Levin, Matthew A ^a   Fischer, Gregory W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; OXYGEN; CARDIOVASCULAR AGENT;

ANESTHESIA; BLOOD PRESSURE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART SURGERY; HUMAN; INTENSIVE CARE; LIVER TRANSPLANTATION; METHEMOGLOBINEMIA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; REVIEW; SEPTIC SHOCK; SHOCK; VASOPLEGIA; ADVERSE EFFECTS; DRUG EFFECTS; HEMODYNAMICS; PATHOPHYSIOLOGY; PROCEDURES; SHOCK, SEPTIC; TREATMENT OUTCOME; VASODILATATION;

CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR AGENTS; HEMODYNAMICS; HUMANS; LIVER TRANSPLANTATION; METHYLENE BLUE; RESUSCITATION; SHOCK, SEPTIC; TREATMENT OUTCOME; VASODILATION; VASOPLEGIA;

EID: 84950327343     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000001045     Document Type: Review

References (117)

1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95
2. Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG, Buffolo E. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998;39:619-23
3. Huet O, Chin-Dustin J. Septic shock: desperately seeking treatment. Clin Sci 2014;126: 31-9
4. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496-9
5. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR Jr, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973-80
6. Morelli A, Donati A, Ertmer C, Rehberg S, Orecchioni A, Di Russo A, Pelaia P, Pietropaoli P, Westphal M. Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. Intensive Care Med 2011;37:963-9
7. Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Landoni G, Pelaia P, Pietropaoli P, Van Aken H, Teboul JL, Ince C, Westphal M. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care 2010;14:R232
8. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, Kahn RJ, Vincent JL. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995;23:259-64
9. Palmer RMJ. The discovery of nitric oxide in the vessel wall. A unifying concept in the pathogenesis of sepsis, Arch Surg 1993;128: 396-401
10. Fischer GW, Bengtsson Y, Scarola S, Cohen E. Methylene blue for vasopressor-resistant vasoplegia syndrome during liver transplantation. J Cardiothorac Vasc Anesth 2010;24:463-6
11. Myles PS, Leong CK, Currey J. Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:571-4
12. Leyh RG, Kofidis T, Strüber M, Fischer S, Knobloch K, Wachsmann B, Hagl C, Simon AR, Haverich A. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass J Thorac Cardiovasc Surg 2003;125:1426-31
13. McDonagh EM, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: methylene blue pathway. Pharmacogenet Genomics 2013;23:498-508
14. Faber P, Ronald A, Millar BW. Methylthioninium chloride: pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass. Anaesthesia 2005;60:575-87
15. Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000;56:247-50
16. Kessler MR. Spurious pulse oximeter desaturation with methylene blue injection. Anesthesiology 1996;65:435-6
17. Sinex JE. Pulse oximetry: principles and limitations. Am J Emerg Med 1999;17:59-67
18. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha. Science 1999;286:1583-7
19. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990;22:1835-40
20. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682-5
21. Stuehr DJ, Kwon NS, Nathan CF, Griffith OW, Feldman PL, Wiseman J. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991;266:6259-63
22. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32
23. Kilbourn RG, Jubran A, Gross SS, Griffith OW, Levi R, Adams J, Lodato RF. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990;172:1132-8
24. Kilbourn RG, Cromeens DM, Chelly FD, Griffith OW. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Crit Care Med 1994;22:1835-40
25. Titheradge MA. NO in septic shock. Biochem Biophys Acta 1999;1411:437-55
26. Taylor BS, Gellar DA. Molecular regulation of the human inducible NO synthase (iNOS) gene. Shock 2000;13:413-24
27. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993;41:77-81
28. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-68
29. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:355-66
30. Singh S, Evans TW. Nitric oxide, the biological mediator of the decade: fact or fiction Eur Respir J 1997;10:699-707
31. Keaney JF Jr, Puyana JC, Francis S, Loscalzo JF, Stamler JS, Loscalzo J. Methylene blue reverses endotoxin-induced hypotension. Circ Res 1994;74:1121-5
32. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993;45:367-74
33. Olstein EH, Woods KS, Ignarro LJ. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys 1982;218:187-98
34. Hata JS, Dellinger PR. Nitric oxide inhibition in the treatment of septic shock. Crit Car Med 1993;45:367-74
35. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol 1981;59:150-6
36. Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets 2012;13:1207-14
37. Beasley D, McGuiggin M. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med 1994;179:71-80
38. Schmidt HH. NO, CO and OH. Endogenous soluble guanylyl cyclase-activating factors. FEBS Lett 1992;307:102-7
39. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 1997;23:553-60
40. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998;30:215-23
41. Kojda G, Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 1999;41:514-23
42. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9
43. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363-70
44. Bardakci H, Kaplan S, Karadeniz U, Ozer C, Bardakci Y, Ozogul C, Birincioglu CL, Cobanoglu A. Methylene blue decreases ischemia-reperfusion (I/R)-induced spinal cord injury: an in vivo study in an I/R rabbit model. Eur Surg Res 2006;38:482-8
45. Gomes WJ, Carvalho AC, Palma JH, Goncąlves I Jr, Buffolo E. Vasoplegic syndrome: a new dilemma. J Thorac Cardiovasc Surg 1994;107:942-3
46. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, Haverich A, Schlag G, Borst HG. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996;61:1714-20
47. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57
48. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J Cardiothorac Surg 2005;28:705-10
49. Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kücükarslan N, Günay C, Demirkilic U, Tatar H. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005;79:1615-9
50. Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thébert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71:1428-32
51. Raja SG, Fida N. Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation Interact Cardiovasc Thorac Surg 2008;7:470-5
52. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000;15:347-53
53. Byrne JG, Leacche M, Paul S, Mihaljevic T, Rawn JD, Shernan SK, Mudge GH, Stevenson LW. Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation. Eur J Cardiothorac Surg 2004;25:327-32
54. Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 2009;120:1664-71
55. Egi M, Bellomo R, Langenberg C, Haase M, Haase A, Doolan L, Matalanis G, Seevenayagam S, Buxton B. Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: a systematic literature review. Ann Thorac Surg 2007;83:715-23
56. Bomberg H, Bierbach B, Flache S, Scheuer C, Novák M, Schäfers HJ, Menger MD. Vasopressin induces rectosigmoidal mucosal ischemia during cardiopulmonary bypass. J Card Surg 2014;29:108-15
57. Dünser MW, Mayr AJ, Tür A, Pajk W, Barbara F, Knotzer H, Ulmer H, Hasibeder WR. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394-8
58. Hayes MA, Yau EH, Hinds CJ, Watson JD. Symmetrical peripheral gangrene: association with noradrenaline administration. Intensive Care Med 1992;18:433-6
59. Bonamigo RR, Razera F, Cartell A. Extensive skin necrosis following use of noradrenaline and dopamine. J Eur Acad Dermatol Venereol 2007;21:565-6
60. Kim EH, Lee SH, Byun SW, Kang HS, Koo DH, Park HG, Hong SB. Skin necrosis after a low-dose vasopressin infusion through a central venous catheter for treating septic shock. Korean J Intern Med 2006;21:287-90
61. Evora PR, Ribeiro PJ, de Andrade JC. Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg 1997;63:1212-3
62. Kofidis T, Sturber M, Wilhelmi M, Anssar M, Simon A, Harringer W, Haverich A. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thorac Cardiovasc Surg 2001;122:823-4
63. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg 2010;22:140-4
64. Evora PR. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock (letter). J Thorac Cardiovasc Surg 2000;119:632-4
65. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003;125:426-7
66. Sparicio D, Landoni G, Pappalardo F, Crivellari M, Cerchierini E, Marino G, Zangrillo A. Methylene blue for lithiuminduced refractory hypotension in off-pump coronary artery bypass graft: report of two cases. J Thorac Cardiovasc Surg 2004;127:592-3
67. Maslow AD, Stearns G, Butala P, Batula P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006;103:2-8
68. Valchanov K, Falter F. Methylene blue for CPB. Anesth Analg 2007;104:1296
69. Grubb KJ, Kennedy JL, Bergin JD, Groves DS, Kern JA. The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. J Thorac Cardiovasc Surg 2012;144:e113-6
70. Ng BK, Cameron AJ. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics 2010;51:194-200
71. Food and Drug Administration. FDA Drug Safety Communication: Serious CNS Re-actions Possible When Methylene Blue Is Given to Patients Taking Certain Psychiatric Medications. 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm. Accessed January 14, 2012
72. Weiner MM, Lin HM, Danforth D, Rao S, Hosseinian L, Fischer GW. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth 2013;27:1233-8
73. Evora PB, Rodrigues AJ, Celotto AC. "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. J Cardiothorac Vasc Anesth 2014;28:e11
74. Landoni G, Pasin L, Di Prima AL, Dossi R, Taddeo D, Zangrillo A. Methylene blue: between scylla (meta-analysis) and charybdis (propensity). J Cardiothorac Vasc Anesth 2014;28:e12-3
75. Weiner MM, Fischer GW. Methylene blue: the Trojan horse. J Cardiothorac Vasc Anesth 2014;28:e13-4
76. Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Dis Sci 2005;50:1771-7
77. Laffi G, Foschi M, Masini E, Simoni A, Mugnai L, La Villa G, Barletta G, Mannaioni PF, Gentilini P. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995;22:1666-73
78. Cheng SS, Berman GW, Merritt GR, Hendrickse A, Fiegel MJ, Teitelbaum I, Campsen J, Wachs M, Zimmerman M, Mandell MS. The response to methylene blue in patients with severe hypotension during liver transplantation. J Clin Anesth 2012;24:324-8
79. Acosta F, Rodriguez MA, Sansano T, Contreras RF, Reche M, Roques V, Beltran R, Robles R, Bueno FS, Ramirez P, Parrilla P. Need for inotropic and/or vasopressor drugs during liver transplantation. Transplant Proc 1999;31:2402-3
80. Aggarwal S, Kang Y, Freeman JA, Fortunato FL, Pinsky MR. Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc 1987;19:54-5
81. Hilmi I, Horton CN, Planinsic RM, Sakai T, Nicolau-Raducu R, Damian D, Gligor S, Marcos A. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl 2008;14:504-8
82. Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay M, Belghiti J, Mantz J. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl 2009;15:522-9
83. Xu ZD, Xu HT, Yuan HB, Zhang H, Ji RH, Zou Z, Fu ZR, Shi XY. Postreperfusion syndrome during orthotopic liver transplantation: a single-center experience. Hepatobiliary Pancreat Dis Int 2012;11:34-9
84. Nanashima A, Pillay P, Crawford M, Nakasuji M, Verran DJ, Painter D. Analysis of postrevascularization syndrome after orthotopic liver transplantation: the experience of an Australian liver transplantation center. J Hepatobiliary Pancreat Surg 2001;8:557-63
85. Ponnudurai RN, Koneru B, Akhtar SA, Wachsberg RH, Fisher A, Wilson DJ, de la Torre AN. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther 2005;27:192-8
86. Ramsay M. The reperfusion syndrome: have we made any progress Liver Transpl 2008;14:412-4
87. de Armas LC, Castillo YA. Is it possible to distinguish between vasoplegic syndrome and postreperfusion syndrome during liver graft reperfusion Anesth Analg 2010;110:969-70
88. Fukazawa K, Pretto EA. The effect of methylene blue during orthotopic liver transplantation on post reperfusion syndrome and postoperative graft function. J Hepatobiliary Pancreat Sci 2011;18:406-13
89. Valentine E, Gregorits M, Gutsche JT, Al-Ghofaily L, Augoustides JG. Clinical update in liver transplantation. J Cardiothorac Vasc Anesth 2013;27:809-15
90. Bezinover D, McQuillan P, Rossignol J, Uemura T, Kadry Z, Janicki P. Vasoplegic shock during liver transplantation: is the preoperative cGMP plasma level a potential predictor of hemodynamic instability Med Sci Monit 2010;16:CS114-7
91. Cao Z, Gao Y, Tao G. Vasoplegic syndrome during liver transplantation. Anesth Analg 2009;108:1941-3
92. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002;94:824-9
93. McGinn PV. Reversal of the haemodynamic features of acute liver failure by methylene blue. Intensive Care Med 1996;22:612
94. Rosique RG, Rosique MJ, Rosique IA, Tirapelli LF, Castro e Silva O Jr, dos Santos JS, Evora PR. Effect of methylene blue on the hemodynamic instability resulting from liver ischemia and reperfusion in rabbits. Transplant Proc 2011;43:3643-51
95. Nunes H, Lebbrec D, Mazmanian M, Capron F, Heller J, Tazi KA, Zerbib E, Dulmet E, Moreau R, Dinh-Xuan AT, Simonneau G, Hervé P. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001;164:879-85
96. Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113:606-14
97. Almeida JA, Riordan SM, Liu J, Galhenage S, Kim R, Bihari D, Wegner EA, Cranney GB, Thomas PS. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol 2007;19:341-6
98. Thomson A, McMillan J, Kerlin P, Strong R. Methylene blue fails to improve hypoxaemia post orthotopic liver transplantation (OLT). Aust N Z J Med 1995;25:262
99. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med 1994;331:1098
100. Roma J, Balbi E, Pacheco-Moreira L, Gonzalez AC, Leal CG, Pousa F, Zynger I, Leite D, Halpern M, Guerra PP, Covelo M, Carius L, Agoglia L, Oliveira A, Enne M. Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report. Transplant Proc 2010;42:601-4
101. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000;133:701-6
102. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;4:1250-6
103. Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, Perez P, Meziani F. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med 2010;36:2019-29
104. Donati A, Conti G, Loggi S, Münch C, Coltrinari R, Pelaia P, Pietropaoli P, Preiser JC. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume Crit Care Med 2002;30:2271-7
105. Cobb JP, Natanson C, Hoffman WD, Lodato RF, Banks S, Koev CA, Solomon MA, Elin RJ, Hosseini JM, Danner RL. N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 1992;176:1175-82
106. Statman R, Cheng W, Cunningham JN, Henderson JL, Damiani P, Siconolfi A, Rogers D, Horovitz JH. Nitric oxide inhibition in the treatment of the sepsis syndrome is detrimental to tissue oxygenation. J Surg Res 1994;57:93-8
107. Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010;22:275-80
108. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 1999;27:913-22
109. López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30
110. Pasin L, Umbrello M, Greco T, Zambon M, Pappalardo F, Crivellari M, Borghi G, Morelli A, Zangrillo A, Landoni G. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc 2013;15:42-8
111. Lomniczi A, Canteros G, McCann SM, Rettori V. Methylene blue inhibits the increase of inducible nitric oxide synthase activity induced by stress and lipopolysaccharide in the medial basal hypothalamus of rats. Neuroimmunomodulation 2000;8:122-7
112. Buzato MA, Viaro F, Piccinato CE, Evora PR. The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: experimental studies in rabbits. Shock 2005;23:582-7
113. Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjørnsson B, Nedashkovsky EV, Bjertnaes LJ. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001;29:1860-7
114. Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002;30:755-62
115. Andresen M, Dougnac A, Diáz O, Hernández G, Castillo L, Bugedo G, Alvarez M, Dagnino J. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care 1998;13:164-8
116. Fernandes D, Sordi R, Pacheco LK, Nardi GM, Heckert BT, Villela CG, Lobo AR, Barja-Fidalgo C, Assreuy J. Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model. J Pharmacol Exp Ther 2009;328:991-9
117. Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med 2006;21:359-63